 YONKERS, N.Y., April 15, 2021 GLOBE NEWSWIRE -- ContraFect Corporation Nasdaq: CFRX, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research, will virtually present the Companys anti-infective portfolio and platform technology of DLAs in the session on Advancing Clinical Superiority of Anti-Infectives to Drive Commercial Success. 